Skip to main content
SpringerPlus

Table 3 Characteristics of patients and the timing of tissue collection

From: Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy

Patient number/age

Previous treatment

EE2 response/biopsy site

  

LHRHa

LHRHa

 

LHRHa

              

1

 

+ Tam

+ ANA

 

+ L

 

TS-1

VNR

 

PTX

 

E

 

EE2

 

L

EE2

 
  

10m

12m

 

3m

 

12m

21m

 

3m

 

4m

 

14m

 

5m

  

Responder liver, local

59

            

^

 

^

   
            

B

 

A

   

2

  

TS-1 +

               

Responder lymph node

 

DTX

ANA

 

E

 

EC

DTX

 

XC

 

L

 

EE2

 

L

EE2

 
 

15m

13m

 

5m

 

13m

24m

 

6m

 

7m

 

14m

 

6m

  

62

            

^

 

^

   
            

B

 

A

   

3

                

H +

 

Non-responder local

      

FEC

XT

 

ANA

 

E

 

EE2

 

FUL

PTX

 
       

3m

12m

 

8m

 

2m

 

4m

 

3m

  

56

     

^

  

^

 

^

   

^

  

^

     

B

  

B

 

B

   

A

  

A

  

E

MPA

 

Tam

 

L

TS-1

 

ANA

 

Tor

 

EE2

 

L

  

Responder skin

4

  

8m

 

9m

 

2m

13m

 

8m

 

2m

 

12m

    

64

        

^

 

^

  

^

^

   
        

B

 

B

  

D

A

   
  

AC

H

 

L

 

Tor

E+H

 

PTX

 

L

 

EE2

 

FuL

  

Responder local

5

 

8m

7m

 

8m

 

6m

1m

 

4m

 

3m

 

8m

    

58

   

^

^

^

^

^

    

^

^

^

   
   

B

B

B

B

B

    

B

D

A

   
 

L

ANA

XC

 

TS-1

 

ANA

Tor

 

PTX

 

ANA

 

EE2

    

Responder local

6

16m

3m

9m

 

3m

 

2m

7m

 

11m

 

3m

 

14m --

    

83

            

^

 

^

   
            

B

 

B

   
  1. ^: the time point when tissue was obtained.
  2. B: before EE2 treatment D: During EE2 treatment; A: After EE2 treatment.
  3. Sample shown in bold letter were used in this study.
  4. Abbreviations: ANA: anastozole; AC: doxorubicine + cyclophosphamide; DTX: docetaxel; E: exemestane; EC: Epirubicine + cydophoshamide; FEC: cydoshsphamide + epirubine+5-FU; FUL: fulvestrant; H: herceptine; L: letrozole; MPA: medroxyprogesterone; PTX: paclitaxel; Tam: tamoxifen; Tor: toremifeme; VNR: vinorelubin; XC: capecitabine + cyclophosphamide; XT: capecitabine + docetaxel.
Back to article page